Sponsored By

Haemonetics Set to Acquire OpSens

Haemonetics says the transaction opens to company to financial and strategic benefits like penetration into the interventional cardiology market.

Katie Hobbins

October 12, 2023

2 Min Read
M&A
Dzmitry Dzemidovich / iStock via Getty Images

Medical technology company Haemonetics has entered into a definitive agreement to acquire OpSens, a medical device company focused on cardiology. Haemonetics will acquire the company by buying all outstanding shares for CAD $2.90 per share in an all-cash transaction “representing a fully diluted equity value of approximately USD $253 million at current exchange rate,” according to the press release.

The transaction opens the company to new financial and strategic benefits including the expansion of its hospital business unit portfolio with OpSens fiber optic sensor technology, used in transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI) procedures, in the interventional cardiology market. The fiber optic sensor portfolio offers Haemonetics access to the market, which has a total addressable market value of approximately $1 billion. OpSens line of products can also be used across different medical and industrial applications, according to the company, adding more avenues for growth and diversification.

Two OpSens products are SavvyWire and OptoWire. SavvyWire is a sensor-guided three-in-one guideware for TAVR procedures and acts as pacing and pressure monitoring. The wire, according to OpSens, advances the workflow of the procedure and enables the potential of shorter patient hospital stays. OptoWire is a pressure guidewire intended to improve outcomes by accurately and consistently measuring Fractional Flow Reserve and diastolic pressure ratio to aid in the diagnosis and treatment of patients with coronary artery disease.

Introducing OpSens products to Haemonetics already-established international markets will also create opportunities for further penetration in additional regions, as will the company’s plan to further expand its hospital business through internal and external R&D, clinical, and other business development efforts.

Of note, the acquisition will be affected by way of an arrangement under the Business Corporations Act (Quebec). The companies said the transaction is expected to close by the end of January 2024.

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like